FDA Approves New Bladder Cancer Treatment Before Surgery - bladder cancer treatment
The FDA approved a new bladder cancer treatment based on the phase 3 VOLGA trial results.

The FDA has approved a new treatment for muscle-invasive bladder cancer (MIBC) in patients who are ineligible for or have refused cisplatin-based chemotherapy.

The regimen combines durvalumab (Imfinzi) with enfortumab vedotin (EV) (Padcev) before surgery, followed by durvalumab as adjuvant therapy after radical cystectomy.

Approval is based on the phase 3 VOLGA trial, which showed the combination reduced the risk of recurrence, progression, or death by 49% compared to surgery alone.

A New Standard of Care

The study’s results were presented at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain, and published in the New England Journal of Medicine.

According to Thomas Powles, chair of Genitourinary Oncology at Barts Cancer Institute, the regimen “reduced the risk of death by 42% with a manageable safety profile.”

About 1 in 4 bladder cancer patients have muscle-invasive disease, and up to half are ineligible for cisplatin due to kidney issues or other health problems.

The VOLGA trial enrolled 695 patients across 25 countries, randomly assigning them to durvalumab-EV, durvalumab-tremelimumab-EV, or cystectomy alone.

At a median follow-up of 22.9 months, estimated 24-month event-free survival was 63.5% with durvalumab-EV versus 45.1% with surgery alone.

The most common adverse events with durvalumab-EV were pruritus, urinary tract infection, anemia, and diarrhea.

Of patients assigned to durvalumab-EV, 97.9% began neoadjuvant treatment, and 84.2% completed it, with 85.0% undergoing cystectomy.

Related Post: Lung Cancer Treatment Shifts to Immune Therapies

Adverse Events and Safety Profile

The trial reported that 71.1% of patients in the durvalumab-EV group experienced grade 3 or higher adverse events (AEs) compared to 50.2% in the control group.

Treatment-related grade 3 or higher AEs occurred in 30.7% of patients receiving durvalumab-EV. There was one treatment-related death in this group, attributed to multiple organ dysfunction syndrome.

Common AEs included skin reactions and peripheral neuropathy, with 48.7% of patients experiencing skin reactions and 17.5% reporting peripheral neuropathy, in addition to pruritus, urinary tract infections, anemia, and diarrhea.

Treatment Adherence and Surgical Outcomes

Adherence to the treatment regimen was high, with 97.9% of patients starting neoadjuvant therapy and 84.2% completing it. 85.0% of patients in the durvalumab-EV group underwent cystectomy, compared to 78.6% in the control group.

The median time from the last neoadjuvant dose to surgery was 42 days. Adverse events led to surgery cancellation in 0.9% of cases and delay in 3.5%.

Post-surgery, 67.4% of patients initiated adjuvant durvalumab, and 54.9% completed the full course. Adverse events caused treatment discontinuation in 21.1% of patients overall, including 11.5% during the adjuvant phase.

Long-Term Outcomes and Future Directions

The study highlighted that subsequent anticancer therapy was required for 12.9% of patients in the durvalumab-EV group after trial treatment, compared to 28.4% in the control group.

Patient-reported quality of life remained stable, with no significant decline from baseline. However, questionnaire completion rates were low, particularly in the control group.

Michiel van der Heijden noted the robust and consistent data on antibody-drug conjugates (ADCs) plus immune checkpoint inhibitors in bladder cancer, suggesting a promising direction for future treatments.